InvestorsHub Logo
Followers 4
Posts 1195
Boards Moderated 0
Alias Born 10/03/2015

Re: jondoeuk post# 18

Tuesday, 08/30/2022 4:36:30 PM

Tuesday, August 30, 2022 4:36:30 PM

Post# of 39
Will the ISPC NK cells work if the mAb is the weakest link? .AFM24 v. cetuximab hold the key to success?

AZ just stopped the trial of monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPSC News